Receivership the end or the path to a new

New Post Public Reply Private Reply Replies (1) Message Board
drugmanrx TedJ #22023
519
Receivership the end or the path to a new beginning?

Quote:
Receivership offers an insolvent company the opportunity to recover and resume business operations. Once the receiver has fulfilled their appointed role, the company can oftentimes be handed back to its directors and shareholders.


https://www.dottoreco.com/blog/what-is-the-di...tion-19813

It would seem logical that a receiver would follow the path out lined by Amber as it would benefit all parties involved, if successful.


Quote:
Hi and thank you for your inquiry,
The company and its staff are intensely focused on optimizing its rapid diagnostic test platform technologies. We have organized clinical trials for our covid, flu, RSV multi-test and anticipate these should begin early May 2023 with the goal of having this test available for the next flu season. Our pre-submission has already been submitted to the FDA and we believe this test will be processed under the EUA.
We are continuing to develop our long covid rapid test striving to have it ready for clinical trials before the end of 2023.

Our CFO and his staff re continuing to work to position the company to submit an S1 before the end of this year. In the meantime, our limited financial resources will continue to be largely focused on the commercialization of our products until such a time sustainable revenues are achieved.

Thank you again for your inquiry and your patience as we work to bring our disruptive technologies to market.

Amber


Amber e-mail validity backed by:

" Et al. Podesta.com representing Quantum Materials Corp. has filed their fourth quarter 2022 lobbying report entering 2023 still in the lobbying process."

https://projects.propublica.org/represent/lob.../301036564

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hyzon Motors Plans Delisting from Nasdaq—What This Means

Updated Category News Views 195

Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...

Continue Reading
Unlock the Potential of Crypto Staking with Keynode.net

Updated Category News Views 113

Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...

Continue Reading
Critical Updates for Rocket Pharmaceuticals Investors Amid Lawsuit

Updated Category News Views 263

Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...

Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference

Updated Category News Views 141

Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...

Continue Reading
SciBase's Strong Growth in Q1 2025: Key Highlights and Future

Updated Category News Views 222

Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...

Continue Reading